• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

监测接受肿瘤疫苗治疗的癌症患者的免疫反应。

Monitoring immune responses in cancer patients receiving tumor vaccines.

作者信息

Walker Edwin B, Disis Mary L Nora

机构信息

Providence Portland Medical Center, Earle A Chiles Research Institute, Robert W Franz Cancer Research Center, Portland, Oregon 97213, USA.

出版信息

Int Rev Immunol. 2003 May-Aug;22(3-4):283-319. doi: 10.1080/08830180305226.

DOI:10.1080/08830180305226
PMID:12745643
Abstract

Clinical evaluation of therapeutic tumor vaccines has resulted in examination and comparison of the types of immune function assays required to monitor tumor antigen-stimulated T cell effector function in immunized patients. Three of the most commonly used assays include ELISPOT, tetramer assay, and cytokine flow cytometry (CFC). Discussed are the method and principles for each assay and an assessment of important methodological, reagent, and data acquisition issues that are relevant for the accurate and effective use of the assays. The sensitivity and utility of the assays and present arguments advocating their integrated use in future immunomonitoring studies are also discussed.

摘要

治疗性肿瘤疫苗的临床评估促使人们对监测免疫患者体内肿瘤抗原刺激的T细胞效应功能所需的免疫功能检测类型进行了检查和比较。三种最常用的检测方法包括酶联免疫斑点法(ELISPOT)、四聚体检测法和细胞因子流式细胞术(CFC)。本文讨论了每种检测方法的方法和原理,并评估了与准确有效使用这些检测方法相关的重要方法学、试剂和数据采集问题。还讨论了这些检测方法的灵敏度和实用性,并提出了支持在未来免疫监测研究中综合使用它们的论据。

相似文献

1
Monitoring immune responses in cancer patients receiving tumor vaccines.监测接受肿瘤疫苗治疗的癌症患者的免疫反应。
Int Rev Immunol. 2003 May-Aug;22(3-4):283-319. doi: 10.1080/08830180305226.
2
Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma.酶联免疫斑点法、细胞因子流式细胞术及四聚体技术在检测黑色素瘤患者对基于树突状细胞的多种肽疫苗的T细胞反应中的应用
Clin Cancer Res. 2003 Feb;9(2):641-9.
3
Methods to monitor immune response and quality control.监测免疫反应及质量控制的方法。
Dev Biol (Basel). 2004;116:219-28; discussion 229-36.
4
Immunological monitoring of cancer vaccine therapy.癌症疫苗治疗的免疫监测
Expert Opin Biol Ther. 2004 Oct;4(10):1677-84. doi: 10.1517/14712598.4.10.1677.
5
Dendritic cell gene therapy.树突状细胞基因治疗。
Surg Oncol Clin N Am. 2002 Jul;11(3):645-60. doi: 10.1016/s1055-3207(02)00027-3.
6
Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.验证用于检测黑色素瘤患者对gp100和MelanA/MART-1免疫反应的HLA-A2四聚体流式细胞术方法、IFNγ实时逆转录聚合酶链反应以及IFNγ酶联免疫斑点法。
J Transl Med. 2008 Oct 22;6:61. doi: 10.1186/1479-5876-6-61.
7
Quantification of tumor-specific T lymphocytes with the ELISPOT assay.采用酶联免疫斑点试验对肿瘤特异性T淋巴细胞进行定量分析。
J Immunother. 2000 May-Jun;23(3):289-95. doi: 10.1097/00002371-200005000-00001.
8
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.癌症疫苗治疗的免疫监测:生物治疗协会主办研讨会的结果
J Immunother. 2002 Mar-Apr;25(2):97-138. doi: 10.1097/00002371-200203000-00001.
9
Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells.用于计数抗原特异性T细胞的ELISPOT和细胞因子流式细胞术检测方法的比较。
J Immunol Methods. 2003 Dec;283(1-2):141-53. doi: 10.1016/j.jim.2003.09.001.
10
Quantitating therapeutically relevant T-cell responses to cancer vaccines.定量分析对癌症疫苗具有治疗相关性的T细胞反应。
Crit Rev Immunol. 2001;21(1-3):287-97.

引用本文的文献

1
Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials.肿瘤浸润淋巴细胞作为癌症疫苗试验的终点。
Front Immunol. 2023 Mar 7;14:1090533. doi: 10.3389/fimmu.2023.1090533. eCollection 2023.
2
Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors.细胞因子诱导的杀伤细胞疗法对恶性实体瘤的肿瘤反应评估。
J Transl Med. 2014 Aug 12;12:215. doi: 10.1186/s12967-014-0215-0.
3
Enhancement of anti-murine colon cancer immunity by fusion of a SARS fragment to a low-immunogenic carcinoembryonic antigen.
融合 SARS 片段至低免疫原性癌胚抗原增强抗鼠结肠癌免疫。
Biol Proced Online. 2012 Feb 3;14:2. doi: 10.1186/1480-9222-14-2.
4
Invasion and destruction of a murine fibrosarcoma by Salmonella-induced effector CD8 T cells as a therapeutic intervention against cancer.沙门氏菌诱导的效应 CD8 T 细胞侵袭和破坏鼠纤维肉瘤作为癌症的治疗干预。
Cancer Immunol Immunother. 2011 Mar;60(3):371-80. doi: 10.1007/s00262-010-0950-x. Epub 2010 Dec 4.
5
Cellular and vaccine therapeutic approaches for gliomas.用于神经胶质瘤的细胞和疫苗治疗方法。
J Transl Med. 2010 Oct 14;8:100. doi: 10.1186/1479-5876-8-100.
6
Improved endpoints for cancer immunotherapy trials.癌症免疫疗法试验的改善终点。
J Natl Cancer Inst. 2010 Sep 22;102(18):1388-97. doi: 10.1093/jnci/djq310. Epub 2010 Sep 8.
7
Development and application of 'phosphoflow' as a tool for immunomonitoring.磷酸流作为免疫监测工具的开发与应用。
Expert Rev Vaccines. 2010 Jun;9(6):631-43. doi: 10.1586/erv.10.59.
8
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.生物标志物发现的新观念;美日肿瘤免疫分子标志物研讨会
J Transl Med. 2009 Jun 17;7:45. doi: 10.1186/1479-5876-7-45.
9
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium.基于癌症疫苗联盟大规模国际能力验证小组结果的HLA肽多聚体检测协调指南。
Cancer Immunol Immunother. 2009 Oct;58(10):1701-13. doi: 10.1007/s00262-009-0681-z. Epub 2009 Mar 4.
10
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI).癌症疫苗联盟(CVC/SVI)开展的两项大规模国际酶联免疫斑点技术能力验证小组的结果及协调指南。
Cancer Immunol Immunother. 2008 Mar;57(3):303-15. doi: 10.1007/s00262-007-0380-6. Epub 2007 Aug 25.